Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination : A Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized Implementation Trial
CONCLUSION: In a prespecified exploratory analysis, modest increases in influenza vaccination rates seen with electronic nudges did not translate into observable improvements in clinical outcomes. Seasonal influenza vaccination should remain strongly recommended.PRIMARY FUNDING SOURCE: Sanofi.PMID:38498876 | DOI:10.7326/M23-2638 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - March 18, 2024 Category: Internal Medicine Authors: Niklas Dyrby Johansen Muthiah Vaduganathan Ankeet S Bhatt Simin Gharib Lee Daniel Modin Brian L Claggett Erica L Dueger Sandrine Samson Matthew M Loiacono Rebecca C Harris Lars K øber Scott D Solomon Pradeesh Sivapalan Jens Ulrik St æhr Jensen Cyril Jea Source Type: research
Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination : A Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized Implementation Trial
CONCLUSION: In a prespecified exploratory analysis, modest increases in influenza vaccination rates seen with electronic nudges did not translate into observable improvements in clinical outcomes. Seasonal influenza vaccination should remain strongly recommended.PRIMARY FUNDING SOURCE: Sanofi.PMID:38498876 | DOI:10.7326/M23-2638 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - March 18, 2024 Category: Internal Medicine Authors: Niklas Dyrby Johansen Muthiah Vaduganathan Ankeet S Bhatt Simin Gharib Lee Daniel Modin Brian L Claggett Erica L Dueger Sandrine Samson Matthew M Loiacono Rebecca C Harris Lars K øber Scott D Solomon Pradeesh Sivapalan Jens Ulrik St æhr Jensen Cyril Jea Source Type: research
Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination : A Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized Implementation Trial
CONCLUSION: In a prespecified exploratory analysis, modest increases in influenza vaccination rates seen with electronic nudges did not translate into observable improvements in clinical outcomes. Seasonal influenza vaccination should remain strongly recommended.PRIMARY FUNDING SOURCE: Sanofi.PMID:38498876 | DOI:10.7326/M23-2638 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - March 18, 2024 Category: Internal Medicine Authors: Niklas Dyrby Johansen Muthiah Vaduganathan Ankeet S Bhatt Simin Gharib Lee Daniel Modin Brian L Claggett Erica L Dueger Sandrine Samson Matthew M Loiacono Rebecca C Harris Lars K øber Scott D Solomon Pradeesh Sivapalan Jens Ulrik St æhr Jensen Cyril Jea Source Type: research
Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination : A Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized Implementation Trial
CONCLUSION: In a prespecified exploratory analysis, modest increases in influenza vaccination rates seen with electronic nudges did not translate into observable improvements in clinical outcomes. Seasonal influenza vaccination should remain strongly recommended.PRIMARY FUNDING SOURCE: Sanofi.PMID:38498876 | DOI:10.7326/M23-2638 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - March 18, 2024 Category: Internal Medicine Authors: Niklas Dyrby Johansen Muthiah Vaduganathan Ankeet S Bhatt Simin Gharib Lee Daniel Modin Brian L Claggett Erica L Dueger Sandrine Samson Matthew M Loiacono Rebecca C Harris Lars K øber Scott D Solomon Pradeesh Sivapalan Jens Ulrik St æhr Jensen Cyril Jea Source Type: research
Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination : A Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized Implementation Trial
CONCLUSION: In a prespecified exploratory analysis, modest increases in influenza vaccination rates seen with electronic nudges did not translate into observable improvements in clinical outcomes. Seasonal influenza vaccination should remain strongly recommended.PRIMARY FUNDING SOURCE: Sanofi.PMID:38498876 | DOI:10.7326/M23-2638 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - March 18, 2024 Category: Internal Medicine Authors: Niklas Dyrby Johansen Muthiah Vaduganathan Ankeet S Bhatt Simin Gharib Lee Daniel Modin Brian L Claggett Erica L Dueger Sandrine Samson Matthew M Loiacono Rebecca C Harris Lars K øber Scott D Solomon Pradeesh Sivapalan Jens Ulrik St æhr Jensen Cyril Jea Source Type: research
Text vs Patient Portal Messaging to Improve Influenza Vaccination Coverage
This randomized clinical trial evaluates and compares the effect of patient portal vs text message reminders on influenza vaccination rates across a health system in the United States. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - March 18, 2024 Category: Internal Medicine Source Type: research
Formulation development of a stable influenza recombinant neuraminidase vaccine candidate
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - March 18, 2024 Category: Allergy & Immunology Authors: Bing LiIrina V. UstyugovaLisa SzymkowiczShaolong ZhuMarin MingKaren Y. Y. FungGuadalupe Cort ésD. Andrew JamesMichael HrynykNausheen RahmanRoger H. BrookesSalvador F. Ausara Sanofi Global Vaccine Drug Product Development, Toronto, ON, Canadab Sanofi Glob Source Type: research
Real-life experience on COVID-19 and seasonal influenza vaccines co-administration in the vaccination hub of the University Hospital of Palermo, Italy
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - March 18, 2024 Category: Allergy & Immunology Authors: Claudio CostantinoWalter MazzuccoArianna ConfortoLivia CiminoAlessia PieriSara RusignoloNicole BonaccorsoFloriana Bravat àLaura PipitoneMartina SciortinoMarcello ToccoElena ZarconeGiorgio GrazianoFabio TramutoCarmelo Massimo MaidaAlessandra CasuccioFranc Source Type: research
Design, synthesis, and antiviral activity of 1-aryl-4-arylmethylpiperazine derivatives as Zika virus inhibitors with broad antiviral spectrum
Bioorg Med Chem. 2024 Mar 12;103:117682. doi: 10.1016/j.bmc.2024.117682. Online ahead of print.ABSTRACTZika virus (ZIKV) disease has been given attention due to the risk of congenital microcephaly and neurodevelopmental disorders after ZIKV infection in pregnancy, but no vaccine or antiviral drug is available. Based on a previously reported ZIKV inhibitor ZK22, a series of novel 1-aryl-4-arylmethylpiperazine derivatives was designed, synthesized, and investigated for antiviral activity by quantify cellular ZIKV RNA amount using RT-qPCR method in ZIKV-infected human venous endothelial cells (HUVECs) assay. Structure-activit...
Source: Bioorganic and Medicinal Chemistry - March 17, 2024 Category: Chemistry Authors: Yingjie Ji Lidan Wang Rui Zhou Xiaotang Yang Siqi Li Shan Cen Yanping Li Source Type: research
Design, synthesis, and antiviral activity of 1-aryl-4-arylmethylpiperazine derivatives as Zika virus inhibitors with broad antiviral spectrum
Bioorg Med Chem. 2024 Mar 12;103:117682. doi: 10.1016/j.bmc.2024.117682. Online ahead of print.ABSTRACTZika virus (ZIKV) disease has been given attention due to the risk of congenital microcephaly and neurodevelopmental disorders after ZIKV infection in pregnancy, but no vaccine or antiviral drug is available. Based on a previously reported ZIKV inhibitor ZK22, a series of novel 1-aryl-4-arylmethylpiperazine derivatives was designed, synthesized, and investigated for antiviral activity by quantify cellular ZIKV RNA amount using RT-qPCR method in ZIKV-infected human venous endothelial cells (HUVECs) assay. Structure-activit...
Source: Bioorganic and Medicinal Chemistry - March 17, 2024 Category: Chemistry Authors: Yingjie Ji Lidan Wang Rui Zhou Xiaotang Yang Siqi Li Shan Cen Yanping Li Source Type: research
Design, synthesis, and antiviral activity of 1-aryl-4-arylmethylpiperazine derivatives as Zika virus inhibitors with broad antiviral spectrum
Bioorg Med Chem. 2024 Mar 12;103:117682. doi: 10.1016/j.bmc.2024.117682. Online ahead of print.ABSTRACTZika virus (ZIKV) disease has been given attention due to the risk of congenital microcephaly and neurodevelopmental disorders after ZIKV infection in pregnancy, but no vaccine or antiviral drug is available. Based on a previously reported ZIKV inhibitor ZK22, a series of novel 1-aryl-4-arylmethylpiperazine derivatives was designed, synthesized, and investigated for antiviral activity by quantify cellular ZIKV RNA amount using RT-qPCR method in ZIKV-infected human venous endothelial cells (HUVECs) assay. Structure-activit...
Source: Bioorganic and Medicinal Chemistry - March 17, 2024 Category: Chemistry Authors: Yingjie Ji Lidan Wang Rui Zhou Xiaotang Yang Siqi Li Shan Cen Yanping Li Source Type: research
Viruses, Vol. 16, Pages 458: Insights from Avian Influenza: A Review of Its Multifaceted Nature and Future Pandemic Preparedness
Kam
Avian influenza viruses (AIVs) have posed a significant pandemic threat since their discovery. This review mainly focuses on the epidemiology, virology, pathogenesis, and treatments of avian influenza viruses. We delve into the global spread, past pandemics, clinical symptoms, severity, and immune response related to AIVs. The review also discusses various control measures, including antiviral drugs, vaccines, and potential future directions in influenza treatment and prevention. Lastly, by summarizing the insights from previous pandemic control, this review aims to direct effective strategies for managing future i...
Source: Viruses - March 17, 2024 Category: Virology Authors: Jianning He Yiu-Wing Kam Tags: Review Source Type: research
Potent HPIV3-neutralizing IGHV5-51 Antibodies Identified from Multiple Individuals Show L Chain and CDRH3 Promiscuity
In this study, we aimed to characterize a set of HPIV3-specific Abs identified in multiple individuals for genetic signatures, epitope specificity, neutralization potential, and publicness. We identified 12 potently neutralizing Abs targeting three nonoverlapping epitopes on HPIV3 F. Among these, six Abs identified from two different individuals used Ig heavy variable gene IGHV 5-51, with five of the six Abs targeting the same epitope. However, despite the use of the same H chain variable (VH) gene, these Abs used multiple different L chain variable genes (VL) and diverse H chain CDR 3 (CDRH3) sequences. Together, these re...
Source: Journal of Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Alexandra A Abu-Shmais Rose J Miller Alexis K Janke Rachael M Wolters Clinton M Holt Nagarajan Raju Robert H Carnahan James E Crowe Jarrod J Mousa Ivelin S Georgiev Source Type: research
Potent HPIV3-neutralizing IGHV5-51 Antibodies Identified from Multiple Individuals Show L Chain and CDRH3 Promiscuity
In this study, we aimed to characterize a set of HPIV3-specific Abs identified in multiple individuals for genetic signatures, epitope specificity, neutralization potential, and publicness. We identified 12 potently neutralizing Abs targeting three nonoverlapping epitopes on HPIV3 F. Among these, six Abs identified from two different individuals used Ig heavy variable gene IGHV 5-51, with five of the six Abs targeting the same epitope. However, despite the use of the same H chain variable (VH) gene, these Abs used multiple different L chain variable genes (VL) and diverse H chain CDR 3 (CDRH3) sequences. Together, these re...
Source: Journal of Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Alexandra A Abu-Shmais Rose J Miller Alexis K Janke Rachael M Wolters Clinton M Holt Nagarajan Raju Robert H Carnahan James E Crowe Jarrod J Mousa Ivelin S Georgiev Source Type: research
Potent HPIV3-neutralizing IGHV5-51 Antibodies Identified from Multiple Individuals Show L Chain and CDRH3 Promiscuity
In this study, we aimed to characterize a set of HPIV3-specific Abs identified in multiple individuals for genetic signatures, epitope specificity, neutralization potential, and publicness. We identified 12 potently neutralizing Abs targeting three nonoverlapping epitopes on HPIV3 F. Among these, six Abs identified from two different individuals used Ig heavy variable gene IGHV 5-51, with five of the six Abs targeting the same epitope. However, despite the use of the same H chain variable (VH) gene, these Abs used multiple different L chain variable genes (VL) and diverse H chain CDR 3 (CDRH3) sequences. Together, these re...
Source: Journal of Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Alexandra A Abu-Shmais Rose J Miller Alexis K Janke Rachael M Wolters Clinton M Holt Nagarajan Raju Robert H Carnahan James E Crowe Jarrod J Mousa Ivelin S Georgiev Source Type: research
